BG103946A - Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак - Google Patents

Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак Download PDF

Info

Publication number
BG103946A
BG103946A BG103946A BG10394699A BG103946A BG 103946 A BG103946 A BG 103946A BG 103946 A BG103946 A BG 103946A BG 10394699 A BG10394699 A BG 10394699A BG 103946 A BG103946 A BG 103946A
Authority
BG
Bulgaria
Prior art keywords
alkyl
phenyl
coa reductase
inhibitor
hmg coa
Prior art date
Application number
BG103946A
Other languages
Bulgarian (bg)
English (en)
Inventor
Shama Kajiji
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG103946A publication Critical patent/BG103946A/bg

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG103946A 1997-06-16 1999-12-03 Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак BG103946A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16
PCT/IB1998/000881 WO1998057633A1 (en) 1997-06-16 1998-06-05 FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER

Publications (1)

Publication Number Publication Date
BG103946A true BG103946A (bg) 2000-07-31

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103946A BG103946A (bg) 1997-06-16 1999-12-03 Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак

Country Status (37)

Country Link
EP (1) EP0986387B1 (hu)
JP (1) JP3713051B2 (hu)
KR (1) KR100392573B1 (hu)
CN (1) CN1259868A (hu)
AP (1) AP9801261A0 (hu)
AR (1) AR013090A1 (hu)
AT (1) ATE235905T1 (hu)
BG (1) BG103946A (hu)
BR (1) BR9810616A (hu)
CA (1) CA2294399C (hu)
CO (1) CO4950607A1 (hu)
DE (1) DE69812933T2 (hu)
DK (1) DK0986387T3 (hu)
DZ (1) DZ2518A1 (hu)
EA (1) EA199901043A1 (hu)
ES (1) ES2196559T3 (hu)
GT (1) GT199800081A (hu)
HN (1) HN1998000091A (hu)
HR (1) HRP980328B1 (hu)
HU (1) HUP0004624A3 (hu)
ID (1) ID23014A (hu)
IL (1) IL132765A0 (hu)
IS (1) IS5259A (hu)
MA (1) MA24569A1 (hu)
NO (1) NO996206L (hu)
NZ (1) NZ500662A (hu)
OA (1) OA11231A (hu)
PA (1) PA8453601A1 (hu)
PE (1) PE82899A1 (hu)
PL (1) PL337651A1 (hu)
PT (1) PT986387E (hu)
SK (1) SK169699A3 (hu)
TN (1) TNSN98088A1 (hu)
TR (1) TR199903074T2 (hu)
UA (1) UA57081C2 (hu)
WO (1) WO1998057633A1 (hu)
ZA (1) ZA985182B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1077949A2 (en) 1998-05-12 2001-02-28 Warner-Lambert Company Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer
AU6256499A (en) * 1998-09-24 2000-04-10 Merck & Co., Inc. A method of treating cancer
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
CA2432137C (en) 2000-12-19 2010-12-21 Pfizer Products Inc. Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4092203B2 (ja) 2000-12-21 2008-05-28 ニトロメッド,インク. 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP2005200419A (ja) * 2004-01-16 2005-07-28 National Health Research Inst 癌治療法
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
AU7445998A (en) 1999-01-04
AU724676B2 (en) 2000-09-28
CO4950607A1 (es) 2000-09-01
JP3713051B2 (ja) 2005-11-02
PL337651A1 (en) 2000-08-28
KR20010013839A (ko) 2001-02-26
DE69812933D1 (de) 2003-05-08
ZA985182B (en) 1999-12-17
EP0986387A1 (en) 2000-03-22
HUP0004624A2 (hu) 2001-10-28
PA8453601A1 (es) 2000-05-24
HRP980328A2 (en) 1999-04-30
HRP980328B1 (en) 2002-06-30
EA199901043A1 (ru) 2000-06-26
CN1259868A (zh) 2000-07-12
DZ2518A1 (fr) 2003-02-01
MA24569A1 (fr) 1998-12-31
BR9810616A (pt) 2000-09-12
PT986387E (pt) 2003-06-30
DK0986387T3 (da) 2003-07-14
IL132765A0 (en) 2001-03-19
AP9801261A0 (en) 1999-12-11
NO996206D0 (no) 1999-12-15
HUP0004624A3 (en) 2002-11-28
UA57081C2 (uk) 2003-06-16
TNSN98088A1 (fr) 2005-03-15
NO996206L (no) 2000-02-15
ATE235905T1 (de) 2003-04-15
SK169699A3 (en) 2000-06-12
DE69812933T2 (de) 2003-11-06
WO1998057633A1 (en) 1998-12-23
IS5259A (is) 1999-11-19
PE82899A1 (es) 1999-08-26
CA2294399A1 (en) 1998-12-23
CA2294399C (en) 2004-03-16
JP2000513031A (ja) 2000-10-03
HN1998000091A (es) 1999-09-29
NZ500662A (en) 2001-10-26
AR013090A1 (es) 2000-12-13
EP0986387B1 (en) 2003-04-02
GT199800081A (es) 1999-12-07
TR199903074T2 (xx) 2000-05-22
ID23014A (id) 1999-12-30
ES2196559T3 (es) 2003-12-16
KR100392573B1 (ko) 2003-07-23
OA11231A (en) 2003-05-26

Similar Documents

Publication Publication Date Title
KR100386229B1 (ko) 히드록시카르바졸화합물의평활근유주및증식의억제
RU2448703C2 (ru) Онкогенное ras-специфичное цитотоксическое соединение и способы его применения
JP6473330B2 (ja) RalGTPアーゼを標的とする抗がん化合物及びその使用方法
JP4130179B2 (ja) 骨髄腫を処置するためのc−kit阻害剤の使用
US20070078142A1 (en) Treatment of tuberous sclerosis associated neoplasms
ES2896735T3 (es) Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida
BG103946A (bg) Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак
IL305317A (en) Preparations and methods for regulating hair growth
KR20010032304A (ko) 알도스 환원효소 억제제 및 글리코겐 포스포릴라제억제제의 혼합물
JP2000510828A (ja) 腫瘍崩壊剤および放射線療法の臨床効果を増強するためのプロテインキナーゼc阻害剤の使用
JP6864379B2 (ja) インドール類似体及びその使用
KR20010078803A (ko) 제약 복합제제
EA001779B1 (ru) Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия
AU2002211862B2 (en) Methods of inducing cancer cell death and tumor regression
AU724676C (en) Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer
US20030114503A1 (en) Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
CZ448699A3 (cs) Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny
KR20000035861A (ko) Aids 치료용 약제를 제조하기 위한 pkc 억제제의 사용 방법
MXPA99011798A (en) FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER
EP3503888A1 (en) Inhibitors of-bcr-abl mutants and use thereof
JP4227121B2 (ja) 神経因性疼痛治療剤
WO2021086912A1 (en) Combined pikfyve and p38 map kinase inhibition for treating cancer
WO2002078706A1 (en) Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the inhibition for the treatment of cancer
WO2024124000A1 (en) Treatment of myeloproliferative diseases and disorders with inhibitors of bet family bdii bromodomain
EA042675B1 (ru) Лиганд рецептора гамк-а